title: Malignant lymphoma induction of rabbits with oral spray of Epstein-Barr virus-related herpesvirus from Si-IIA cells (HTLV-II-transformed Cynomolgus cell line): a possible animal model for Epstein-Barr virus infection and subsequent virus-related tumors in humans.
abstract: Malignant lymphoma (ML) was induced in eight of nine rabbits inoculated by oral spray of the cell-free pellets from Si-IIA culture (HTLV-II-transformed leukocyte cell line of the Cynomolgus-producing Epstein-Barr virus (EBV)-related herpesvirus) after 64-141 days. None of the rabbits inoculated with EBV from B-95-8 cells or HTLV-II from MOT cells developed ML. Malignant lymphomas were usually of diffuse, large-cell or mixed type. HTLV-II infection was excluded by the polymerase chain reaction (PCR) and the particle agglutination test. EBV-encoded RNA-1 and EBV-related DNA were detected in the tumor tissues by in situ hybridization and PCR, respectively. Anti-viral capsid antigen of EBV antibody (anti-VCA) was observed 3 weeks after oral inoculation of Si-IIA cell-free pellets. Polymerase chain reaction revealed continuous detection of EBV-related virus DNA in the peripheral blood leukocytes from 3 days after oral inoculation. These results show that ML induced orally with Si-IIA cell-free pellets was caused by EBV-related herpesvirus harbored by Si-IIA cells. Oral spray of EBV from B-95-8 also induced EBV infection in rabbits, which was confirmed both by the presence of anti-VCA and by PCR. These oral infection and malignant lymphoma induction systems of rabbit using EBV-related virus from Si-IIA or human EBV are useful animal models for the study of EBV infection and EBV-related lymphomas in humans.
authors.affiliation: Second Department of Pathology, Okayama University Medical School, Japan.
authors.forename: T R
authors.initials: TR
authors.lastname: Koirala
authors.forename: K
authors.initials: K
authors.lastname: Hayashi
authors.forename: H L
authors.initials: HL
authors.lastname: Chen
authors.forename: H
authors.initials: H
authors.lastname: Ino
authors.forename: N
authors.initials: N
authors.lastname: Kariya
authors.forename: H
authors.initials: H
authors.lastname: Yanai
authors.forename: C R
authors.initials: CR
authors.lastname: Choudhury
authors.forename: T
authors.initials: T
authors.lastname: Akagi
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000956:Antigens, Viral / Q000276:immunology; D036022:Capsid Proteins; D004195:Disease Models, Animal; D005260:Female; D006566:Herpesviridae Infections / Q000821:virology*; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000472:pathogenicity*; D006801:Humans; D017403:In Situ Hybridization; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008099:Liver / Q000473:pathology / Q000821:virology; D008223:Lymphoma / Q000821:virology*; D012367:RNA, Viral / Q000378:metabolism; D011817:Rabbits; D013154:Spleen / Q000473:pathology / Q000821:virology; D014412:Tumor Virus Infections / Q000821:virology*
chemical_list: D000956:Antigens, Viral; D036022:Capsid Proteins; C041788:Epstein-Barr viral capsid antigen; C099537:Epstein-Barr virus encoded RNA 1; D012367:RNA, Viral